Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare progression-free survival (PFS) of randomised metastatic RCC patients receiving sorafenib 400 mg bid versus standard therapy (interferon alpha-2a) as a first-line therapy.
Inclusion criteria
- unresectable and/or metastatic renal cell carcinoma